Drug intelligence / Profile preview

DWC202002

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC202002 is a small molecule drug candidate developed by Daewoong Pharmaceutical. Its precise mechanism of action, molecular target, and therapeutic indication have not been publicly disclosed. The compound has been evaluated in at least one phase 1 clinical trial designed to assess drug-drug interactions with other investigational agents (DWP16001 and DWC202001) in healthy male adults. As of the latest available information, its development status remains pending and no active indications or detailed pharmacological data are available[1][2][3][4].

Beyond the preview

Go deeper on DWC202002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202002.

Explore the full profile